FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2017004575> ?p ?o ?g. }

• W2017004575 endingPage "1275" @default.
• W2017004575 startingPage "1269" @default.
• W2017004575 abstract "1 The effects of fluvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, on the vascular angiotensin converting enzyme (ACE) activity in hyperlipidaemic rabbits were compared with those of enalapril, an ACE inhibitor. 2 Rabbits were fed a 1.5% cholesterol containing diet or normal diet for 16 weeks and treated with either fluvastatin or enalapril in the diet at the respective doses of 2 and 10 mg kg−1 day−1. The total cholesterol, triglyceride and phospholipid levels in serum were significantly increased in rabbits fed the high cholesterol diet. Treatment with fluvastatin but not enalapril resulted in a decrease in serum lipids. 3 The vascular ACE activities assessed via the cleavage rate from synthetic substrate in the aortic arches and upper thoracic aortae were increased by 8 to 10 times when the rabbits were made hyperlipidaemic. Fluvastatin as well as enalapril significantly lowered the tissue ACE in the aortae. 4 The ACE activities in serum did not alter in hyperlipidaemic rabbits either in the presence or absence of fluvastatin. The serum ACE activity was lowered by enalapril. 5 The lipid peroxide in serum as well as the plaque area in the thoracic aorta was significantly increased in the cholesterol diet-fed rabbits. Treatment with fluvastatin or enalapril reduced both serum lipid peroxide and plaque formation. The relaxant responses to acetylcholine (ACh) were significantly suppressed in the cholesterol-fed rabbits. Treatment with fluvastatin or enalapril significantly reversed the suppression of ACh-induced relaxation. 6 It seems that the reduction of vascular ACE is not coupled to lipids and ACE activity in serum, but rather to lipid peroxidation. Thus, the decrease in vascular ACE activity by fluvastatin as well as the lipid-lowering effect may reduce the risk of atherosclerosis progression in the vasculature." @default.
• W2017004575 created "2016-06-24" @default.
• W2017004575 creator A5007918106 @default.
• W2017004575 creator A5011318222 @default.
• W2017004575 creator A5013084374 @default.
• W2017004575 creator A5032095103 @default.
• W2017004575 creator A5033975892 @default.
• W2017004575 creator A5051288623 @default.
• W2017004575 date "1996-11-01" @default.
• W2017004575 modified "2023-09-29" @default.
• W2017004575 title "Inhibitory effects of fluvastatin, a new HMG-CoA reductase inhibitor, on the increase in vascular ACE activity in cholesterol-fed rabbits" @default.
• W2017004575 cites W1851747244 @default.
• W2017004575 cites W1968034182 @default.
• W2017004575 cites W1970442360 @default.
• W2017004575 cites W1973494669 @default.
• W2017004575 cites W1976409921 @default.
• W2017004575 cites W1977884590 @default.
• W2017004575 cites W1985259557 @default.
• W2017004575 cites W1986499415 @default.
• W2017004575 cites W1987578442 @default.
• W2017004575 cites W1990063973 @default.
• W2017004575 cites W1992167081 @default.
• W2017004575 cites W1994918206 @default.
• W2017004575 cites W1995359519 @default.
• W2017004575 cites W2014820285 @default.
• W2017004575 cites W2019729784 @default.
• W2017004575 cites W2031963160 @default.
• W2017004575 cites W2050177211 @default.
• W2017004575 cites W2069445171 @default.
• W2017004575 cites W2071782926 @default.
• W2017004575 cites W2075607851 @default.
• W2017004575 cites W2077901889 @default.
• W2017004575 cites W2087375731 @default.
• W2017004575 cites W2089747265 @default.
• W2017004575 cites W2092394510 @default.
• W2017004575 cites W2123696429 @default.
• W2017004575 cites W2128635872 @default.
• W2017004575 cites W2129925176 @default.
• W2017004575 cites W2134221745 @default.
• W2017004575 cites W2149982036 @default.
• W2017004575 cites W2159659126 @default.
• W2017004575 cites W2407292559 @default.
• W2017004575 cites W2462703090 @default.
• W2017004575 cites W2469805673 @default.
• W2017004575 cites W4254363271 @default.
• W2017004575 cites W4293247451 @default.
• W2017004575 doi "https://doi.org/10.1111/j.1476-5381.1996.tb16032.x" @default.
• W2017004575 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1915883" @default.
• W2017004575 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8937733" @default.
• W2017004575 hasPublicationYear "1996" @default.
• W2017004575 type Work @default.
• W2017004575 sameAs 2017004575 @default.
• W2017004575 citedByCount "53" @default.
• W2017004575 countsByYear W20170045752013 @default.
• W2017004575 countsByYear W20170045752014 @default.
• W2017004575 countsByYear W20170045752017 @default.
• W2017004575 countsByYear W20170045752018 @default.
• W2017004575 crossrefType "journal-article" @default.
• W2017004575 hasAuthorship W2017004575A5007918106 @default.
• W2017004575 hasAuthorship W2017004575A5011318222 @default.
• W2017004575 hasAuthorship W2017004575A5013084374 @default.
• W2017004575 hasAuthorship W2017004575A5032095103 @default.
• W2017004575 hasAuthorship W2017004575A5033975892 @default.
• W2017004575 hasAuthorship W2017004575A5051288623 @default.
• W2017004575 hasBestOaLocation W20170045751 @default.
• W2017004575 hasConcept C104950815 @default.
• W2017004575 hasConcept C126322002 @default.
• W2017004575 hasConcept C134018914 @default.
• W2017004575 hasConcept C134651460 @default.
• W2017004575 hasConcept C181199279 @default.
• W2017004575 hasConcept C185592680 @default.
• W2017004575 hasConcept C27016395 @default.
• W2017004575 hasConcept C2775940317 @default.
• W2017004575 hasConcept C2776329913 @default.
• W2017004575 hasConcept C2778163477 @default.
• W2017004575 hasConcept C2778417548 @default.
• W2017004575 hasConcept C2779611605 @default.
• W2017004575 hasConcept C55493867 @default.
• W2017004575 hasConcept C71924100 @default.
• W2017004575 hasConcept C84393581 @default.
• W2017004575 hasConceptScore W2017004575C104950815 @default.
• W2017004575 hasConceptScore W2017004575C126322002 @default.
• W2017004575 hasConceptScore W2017004575C134018914 @default.
• W2017004575 hasConceptScore W2017004575C134651460 @default.
• W2017004575 hasConceptScore W2017004575C181199279 @default.
• W2017004575 hasConceptScore W2017004575C185592680 @default.
• W2017004575 hasConceptScore W2017004575C27016395 @default.
• W2017004575 hasConceptScore W2017004575C2775940317 @default.
• W2017004575 hasConceptScore W2017004575C2776329913 @default.
• W2017004575 hasConceptScore W2017004575C2778163477 @default.
• W2017004575 hasConceptScore W2017004575C2778417548 @default.
• W2017004575 hasConceptScore W2017004575C2779611605 @default.
• W2017004575 hasConceptScore W2017004575C55493867 @default.
• W2017004575 hasConceptScore W2017004575C71924100 @default.
• W2017004575 hasConceptScore W2017004575C84393581 @default.
• W2017004575 hasIssue "6" @default.
• W2017004575 hasLocation W20170045751 @default.
• W2017004575 hasLocation W20170045752 @default.

• next